FDA approval to addition of OS Data in labelling of Gilteritinib

-

The US Food and Drug Administration has approved the addition of overall survival (OS) data in labelling process of Gilteritinib, a cancer drug which was indicated for adult patients who had relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. FLT3 is a receptor tyrosine kinase with important roles in cell survival and proliferation. It is mutated in one -third of AML patients. Gliteritinib acts as an inhibitor of AXL receptor tyrosine kinase, an enzyme in humans encoded by AXL gene . The AXL gene plays a crucial role in facilitating immune escape and drug resistance by cancer cell, leading to metastatic cancers.  

According to results, treatment with the FLT3-targeted therapeutic Gilteritinib has shown improved survival for patients with relapsed or refractory acute myeloid leukemia harbouring an FLT3 mutation compared with standard chemotherapy regiments.

Get to know more such interesting news about oncology at: https://bit.ly/2KYdGMJ


Comments

Post a Comment

Popular posts from this blog

-
Image
Researchers have found that artificial intelligence recognizes new breast cancer types that respond differently to a treatment. Using artificial intelligence, five new types of diseases were uncovered, each of them matched to different personalized treatments. The study applied AI and a machine-learning approach to gene sequences and molecular data from breast tumors, to reveal crucial differences among cancers that had previously been lumped into one type of disease. The researchers applied the AI-compatible computer software to a vast array of data available in the field of genetics, a molecular and cellular constituent of breast tumors, and data on patient survival. The goal of the study is to apply this technique different types of cancer and get information about their response and sensitivity to treatment, part of evolution, and how to tackle drug resistan problem.          
Read more

Tumour size helps doctors determine stages of breast cancer

-
Image
Tumour size is an important consideration in determining breast cancer staging.  Every breast cancer patient’s disease condition is different, but its stage provides a general indication of a patient’s treatment options and outlook.  The overall stages of cancer range from 0 to 4. Stage 0 means that breast cancer is at a very early stage and has not yet spread. Stage 4 is late-stage breast cancer, in which cancer has spread to other parts of the body. people with early-stage breast cancer are likely to have smaller tumours that are easier to treat. But, large tumours indicate late-stage breast cancer, which may be more difficult to treat. To determine the severity of the disease, size of primary breast cancer a tumour is measured at its widest point and unit of measure is millimetres(mm) or centimetres(cm). Apart from tumour size, there are also other factors that help in determining the stages of breast cancer. These include the status of lymph nodes, appearance...
Read more